



Published in final edited form as:

J Mol Biol Mol Imaging. 2014 ; 1(2): .

Transfer RNA as a source of small functional RNA

Megumi Shigematsu, Shozo Honda, and Yohei Kirino*

Computational Medicine Center, Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, USA

Abstract

Since their discovery in the 1950s, transfer RNAs (tRNAs) have been best known as adapter molecules that play a central role in translating genetic information. However, recent biochemical and bioinformatic evidence has led to a previously unexpected conceptual consensus that tRNAs are not always end products; they further serve as a source of small functional RNAs. In many organisms, specific tRNA fragments are produced from mature tRNAs or their precursor transcripts not as random degradation products, but as functional molecules involved in many biological processes beyond translation. In this review, we summarize recent studies of tRNA fragments that have provided new insights into tRNA biology by examining the molecular functions of tRNA fragments and proteins with which they interact.

Keywords

tRNA; tRNA fragment; tRNA half; tRF; Argonaute

Introduction

The groundbreaking development of next-generation sequencing (NGS) technologies has dramatically advanced our understanding of the cellular transcriptome, revealing that non-protein-coding regions of the genome are widely transcribed, and the generated non-coding RNAs (ncRNAs) play important roles in normal biological processes and diseases [1]. Within the diverse group of ncRNAs, the functional significance is particularly evident for small regulatory RNAs which direct the highly-specific regulation of gene expression by recognizing their complementary RNA targets [2–4]. To date, the following three major classes of small regulatory RNAs have been reported: microRNAs (miRNAs), short-interfering RNAs (siRNAs), and PIWI-interacting RNAs (piRNAs). The definitive features of these RNAs are their short lengths of 20–31 nucleotides (nt) and their interaction with Argonaute family proteins to form effector ribonucleoprotein complexes. miRNAs, the best-studied class of small regulatory RNAs, repress complementary target mRNA expression, which is estimated to regulate the expression of most protein-coding genes [5, 6]. Thus, small regulatory RNAs constitute one of the most abundant gene expression regulators and exhibit a tremendous impact on all biological processes by shaping the transcriptome.

*Correspondence: Yohei Kirino, Computational Medicine Center, Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, 1020 Locust Street, JAH Suite #M77, Philadelphia, PA 19107, USA; Tel: 215-503-8648; Fax: 215-503-0466; Yohei.Kirino@jefferson.edu.

Although such small RNAs have been the focus of much attention over the recent years, NGS studies combined with RNA biochemical studies have revealed the existence of many different other functional small ncRNAs in the cellular transcriptome, including small RNA fragments from transfer RNAs (tRNAs), which we will highlight in this review.

Unexpected expansion of the tRNA world

tRNAs are universally expressed in all three domains of life, and play a central role in gene expression as adapter molecules that translate codons in mRNA into amino acids in protein. Since their discovery in the 1950s, extensive studies have clearly defined their biological properties [7]. tRNAs are 70–90 nt in length and form as cloverleaf secondary structure containing three major loops (D-, T-, and anticodon loops) and four stems (acceptor-, D-, T-, and anticodon stems) (Figure 1). These loops and stems fold into an L-shaped tertiary structure. Over 500 tRNA genes are encoded in the human genome [8], and tRNAs have long half-lives, estimated on the order of days in tissues [9, 10]. Active transcription from multiple sites and high stability place tRNAs among the most abundant RNA molecules, occupying around 15% of the cellular RNA transcriptome.

Considering their abundance and well-defined biological role in translation, it is not surprising that RNA fragments from tRNAs were regarded as non-functional degradation intermediates for a long time. The apparent presence of abundant tRNA fragments in early NGS studies was often ignored. However, the combined biochemical evidence from many years of tRNA biology has recently brought the field to a previously unexpected conceptual consensus: specific tRNA fragments are widely expressed not as random degradation products but as functional molecules in many different cells of various organisms [11–15]. The expression of tRNA fragments does not usually affect mature tRNA pools. Instead, it is involved in normal biological processes beyond translation and in diseases; thus, studies of tRNA fragment have provided new insights into tRNA biology. The first evidence of the presence of functional tRNA fragments was reported in 1999; conditioned medium from human urinary bladder carcinoma cells contained tRNA fragments that exhibited an inhibitory effect on endothelial cell growth [16]. In this review, we will summarize the subsequent accumulation of findings, as displayed in Table 1, concerning functional tRNA fragments whose molecular functions and/or associated proteins have been experimentally examined and validated.

Classification of tRNA fragments: tRNA halves and tRFs

Mature tRNAs are produced from precursor tRNAs (pre-tRNAs), which undergo several steps during maturation [11]. In the first step, pre-tRNAs are transcribed from tRNA genes by RNA polymerase III. The 5'-leader and 3'-trailer sequences of the pre-tRNAs are subsequently removed by endonucleolytic cleavage catalyzed by RNase P and RNase Z, respectively. The trinucleotides “CCA” are then attached to the 3'-termini of tRNAs by CCA-adding enzyme. tRNAs also undergo modification events to create many different non-canonical bases at various positions. Finally, the resultant mature tRNAs are aminoacylated by their cognate aminoacyl-tRNA synthetases, and participate in translation

on the ribosome. Both pre-tRNAs and mature tRNAs serve as substrates for the production of tRNA fragments.

Following the proposed nomenclature [14], tRNA fragments identified so far can be classified into two groups: tRNA halves and tRNA-derived fragments (tRFs) [11–15]. tRNA halves are composed of 30–35 nt fragments derived from either the 5'- or 3'-part of fully matured tRNAs with processed 5'- and 3'-CCA termini (Figure 1). Shorter than tRNA halves, tRFs range from 13–20 nt in length, and can presently be subclassified into four subgroups: 5'-tRFs, 3'-CCA tRFs, 3'-U tRFs, and 5'-leader-exon tRFs (Figure 1). The 5'-tRFs and 3'-CCA tRFs correspond to the 5'- and 3'-parts of mature tRNAs containing processed 5'- and 3'-CCA termini, respectively. Since 5'-leader sequences are absent, 5'-tRFs are formed by cleavage in the D-loop after RNase P-catalyzed removal of 5'-leader sequences. The presence of CCA sequences in 3'-CCA tRFs indicates that the cleavage in the T-loop that produces the 3'-CCA tRFs occurs after 3'-terminal maturation by CCA-adding enzyme. Because these tRFs and tRNA halves coexist (e.g., 5'-tRFs were purified together with 5'-tRNA halves in Dicer-immunoprecipitates) [17–21], the tRNA halves, as well as mature tRNAs, may also be a direct precursor of these tRFs. The 3'-U tRFs are derived from the 3'-leader sequence of pre-tRNAs that harbor 3'-terminal uridine stretches, which result from transcriptional termination by RNA polymerase III at thymidine tracts. The 5'-leader-exon tRFs, another class of precursor-derived tRFs, include the 5'-leader and the 5'-part of mature tRNAs.

tRNA halves as stress-responsive elements

Eukaryotic tRNA halves were first identified in *Tetrahymena* as starvation-induced molecules [22]. Their expression was subsequently shown to be triggered in a wide variety of organisms by a variety of stress stimuli, such as oxidative stress, heat/cold shocks, and UV irradiation [21, 23–30]. Therefore, tRNA halves are also known as tRNA-derived stress-induced RNAs (tiRNAs) [25], although they are also detected under non-stressed conditions [17, 31–33]. In mammalian cells, Angiogenin (ANG), a member of the RNase A superfamily, was discovered to be the enzyme that cleaves the anticodon loops of mature tRNAs to produce tRNA halves [25, 26]. Rny1p, a member of the RNase T2 family, is responsible for this anticodon cleavage in yeast [24]. RNH1, an ANG inhibitor interacting with ANG in the cytoplasm, was shown to be a regulatory factor for ANG cleavage [25]. Interestingly, a tRNA modification and the enzymes that catalyze it were also shown to be regulatory factors for the production of tRNA halves. A number of tRNAs can be methylated by Dnmt2 and NSun2 methyltransferases; this modification protects the modified tRNAs from stress-induced cleavage [19, 34, 35]. It is noteworthy that the stabilities and abundances of the two fragments supposedly produced from the same anticodon cleavage, the 5'- and 3'-tRNA halves, can be asymmetric depending on the organism and the conditions [19, 21, 26, 31].

Fascinatingly, stress-induced tRNA halves promote the phosphor-eIF2 α -independent formation of stress granules (SGs) [36]. Because an SG encompasses stalled translation pre-initiation complexes together with poly A-tailed mRNAs for translational repression and future translational induction [37], tRNA halves may play an important signaling role in

regulating gene expression by targeting translation initiation complex. The ability to promote SG assembly varies depending on the species of the tRNA halves. Only 5'-tRNA halves, not 3'-tRNA halves, show SG formation activity; a 5'-tRNA half from tRNA^{Ala} shows the strongest activity [36]. These observations raise the possibility that tRNA halves might interact with specific factors through the certain sequence motifs within tRNA. This implies that the generation of tRNA halves may be controlled in both qualitative and quantitative ways to produce different amounts of selected tRNA half-species for adaptation against different stresses.

Recent studies provide compelling evidence that the enhanced expression of tRNA halves is involved in human disease as a source of stress response molecules. NSun2, an RNA methyltransferase whose genetic mutations are associated with neurodevelopmental disorders, methylates a majority of expressed tRNAs to generate the m⁵C modification [19]. tRNAs lacking this modification in NSun2-mutated patient fibroblasts or Nsun2-deficient mice are more susceptible to anticodon cleavage by ANG. As a result, 5'-tRNA halves accumulate in NSun2-deficient cells, which is both necessary and sufficient to trigger cellular stress responses in those cells. Because cellular stress responses often precede apoptosis, it is not surprising that stress responses activated by the accumulation of the tRNA halves result in increased apoptosis in the neurons of NSun2-deficient mice [19]. Contrary to their causative effect on apoptosis, tRNA halves produced from ANG cleavage have also been reported to inhibit apoptosis by interacting with cytochrome c in osmotically-stressed mouse embryonic fibroblasts [38].

The other example of disease-related tRNA fragments has been observed in cells with defective CLP1, which is a multifunctional kinase whose genetic mutations are found in neurodegenerative diseases [39–41]. CLP1 associates with the tRNA-splicing endonuclease (TSEN) complex and contributes to tRNA splicing by phosphorylating the 5'-ends of 3'-tRNA halves, which are themselves the products of TSEN complex-catalyzed removal of the anticodon intron of pre-tRNAs [42]. CLP1-deficient mice experience neurodegeneration and accumulate a 5'-leader-exon tRF derived from tRNA^{Tyr} that leads to oxidative stress-induced cell death by promoting p53 phosphorylation [40, 43]. The catalytically-inactive CLP1 mutant derived from patients with neurological diseases impairs TSEN-cleavage of pre-tRNA and increases the sensitivity to oxidative stress [39, 40]. Shaffer *et al.* further demonstrated the toxicity of the 5'-phosphate-lacking 3'-tRNA half from tRNA^{Tyr} in fibroblasts and neural cells [39]. Taken together, these results suggest that accumulation of aberrant tRNA fragments resulting from deficient CLP1 and TSEN activities could be involved in the pathogenesis of neurological diseases.

Global translational inhibition induced by tRNA halves and tRFs

When ANG has been reported to be responsible for the production of tRNA halves under stress conditions, transfection of 5'-tRNA halves, but not 3'-tRNA halves, has been shown to inhibit global translation in human cells [25]. Ivanov *et al.* then revealed the molecular mechanism of the translational inhibition: a 5'-tRNA half from tRNA^{Ala} displaces eIF4G/A and eIF4E/G/A (eIF4F) from uncapped RNA and m⁷G-capped RNA, respectively [44]. YB-1, a multifunctional DNA/RNA-binding protein, was found to strongly associate with

the 5'-tRNA half and mediate the translational inhibition and SG formation. Interestingly, a terminal oligo-G motif present in certain 5'-tRNA halves, such as the 5'-tRNA halves from tRNA^{Ala} and tRNA^{Cys}, has been shown to be required for the translational repression [44]. Because the tRNA halves detected in the cells are not limited to those that contain the motif, it remains to be determined whether or not tRNA halves utilize other mechanisms for translational regulation. Translational inhibition induced by tRNA halves was also suggested in plant. The phloem sap of pumpkin contains many 5'- and 3'-tRNA halves, and sap-derived RNA exhibits global translational inhibition [45]. The translational inhibition is likely to be mediated by tRNA halves (or nicked-tRNAs), because the study also showed that RNase-treated, fragmented tRNAs inhibited translation.

In addition to tRNA halves, tRFs have also been reported to be involved in global translational inhibition in human cells. A 19 nt 5'-tRF derived from tRNA^{Gln} decreased the expression of a reporter gene that did not have a sequence complementary to that of the 5'-tRF, suggesting that non-specific translational repression is mediated by this 5'-tRF [46]. It is intriguing that the conserved “GG” dinucleotide in the 3'-region of this tRF is required for translation repression. Because 5'-tRFs were detected in the polysome fraction, interaction of 5'-tRFs with the ribosome may contribute to translation repression [46]. Indeed, a 5'-tRF derived from tRNA^{Val}, one of the most abundant tRFs in halophilic archaea, associates with the ribosome and represses translation by interfering with peptide bond formation [47].

tRFs bound to Argonaute family proteins

Although the above-mentioned translational inhibitions are not sequence-specific and their mechanisms are completely different from that of miRNA-mediated regulation, it has become apparent that some tRNA fragments act as miRNAs or other small regulatory RNAs by binding to Argonaute family proteins. Argonaute family proteins can be divided into two subclasses: AGO and PIWI [2–4]. AGO proteins are ubiquitously expressed in all tissues and bind to miRNAs and siRNAs that are 20–23 nt in length. In contrast, PIWI proteins are predominantly expressed in the germline (and sometimes in cancers [48]), and interact with 26–31 nt PIWI-interacting RNAs (piRNAs). miRNAs and siRNAs are processed from hairpin-structured or double-stranded precursor RNAs by Dicer endonuclease, while piRNAs are believed to be generated from long single-stranded RNAs by Dicer-independent biogenesis.

The development of antibodies against Argonaute family proteins has enabled the immunoprecipitation of small RNA fractions associated with these endogenous proteins. This has allowed identification of many tRNA fragments, as well as the above-mentioned small regulatory RNAs, as Argonaute-binding small RNAs. Immunoprecipitation of AGO proteins identified significant amounts of tRNA fragments in *Drosophila* [49], *Bombyx* [18], and *Arabidopsis* [50]. In human, 5'-tRFs, 3'-CCA tRFs, and 3'-U tRFs have been reported to bind to AGO proteins [51–54]. Although mature tRNAs do not meet the structural criteria for canonical Dicer substrates, the biogenesis of some tRFs have been reported to be dependent on Dicer in human [51, 53, 55, 56] and mouse [57]. Alternatively, ANG or other enzymes were proposed to be responsible for Dicer-independent biogenesis of AGO-bound tRFs [54]. RNase Z cleavage produces 3'-U tRFs from pre-tRNAs in a Dicer-independent

manner [51, 58]. Thus, tRFs produced through both Dicer-dependent and -independent pathways have been reported to bind to AGO proteins. It is noteworthy that tRFs are asymmetrically loaded onto respective AGO proteins [51, 52, 54]. For example, among the four human AGO proteins (AGO1-4), 3'-CCA tRFs and 3'-U tRFs were shown to preferably associate with AGO3 and AGO4 compared to the other two [51]. This asymmetric loading of tRFs onto different AGO proteins could have significance when considering their function and biogenesis pathway.

Immunoprecipitation of PIWI proteins has also led to the identification of tRNA fragments in human [59], marmoset [60], *Drosophila* [61], *Trypanosoma* [62], and *Tetrahymena* [63, 64], suggesting that tRNA fragments are widely conserved PIWI-binding factors. The biogenesis mechanisms leading to these piRNA-like tRNA fragments remain to be determined. A PIWI protein essential for growth in *Tetrahymena*, TWI12, binds tightly to 3'-CCA tRFs [63]. TWI12 itself is proposed to recognize the tertiary structure of full-length tRNAs and cleave them within the T-loop to generate 3'-CCA tRFs. The production of 3'-CCA tRFs and their interaction with TWI12 are necessary to stabilize, localize, and stimulate Xrn2 exonuclease for nuclear RNA processing, indicating a novel role for tRFs in RNA metabolism [64].

Targeted gene silencing by tRFs and tRNA halves

When tRFs are bound to AGO proteins, they are expected to act as miRNAs and repress specific gene expression by recognizing complementary target mRNAs [2–4]. Therefore, targets for these tRFs can be explored through bioinformatics approaches or through biochemical purification of AGO-bound target RNAs. As in the case of miRNAs [2–4], imperfect tRF-target RNA base pairing could induce translational silencing, whereas perfect base pairing could trigger exonucleolytic decay of the target mRNAs.

One of the first studies describing the function of AGO-tRF complexes was obtained from virus research. It has been long known that retroviruses use host tRNA as a primer for reverse transcription during the first step of retroviral replication. Yeng *et al.* showed that an 18 nt 3'-CCA tRF derived from one such tRNAs, tRNA^{Lys}, associates with AGO2 and targets the primer-binding site (PBS) of human immunodeficiency virus type 1 (HIV-1) [65]. This 3'-CCA tRF directs AGO2-mediated cleavage of the complementary PBS sequence, thereby silencing PBS-containing reporter gene and an HIV-1 gene. Because endogenous retroviral sequences are found extensively in the human genome and 3'-tRFs are highly complementary to them [54], tRF-directed pathways may also have a role in silencing endogenous viral elements. While these reports suggest tRFs act as negative factors for viral expression, positive effects of tRFs on viral replication have also been reported. Infection with human respiratory syncytial virus (RSV) leads to accumulation of 5'-tRFs that are generated by ANG-mediated cleavage at sites adjacent to 5'-end of the anticodon-loop [66]. At least one of the accumulated 5'-tRFs, a 5'-tRF derived from tRNA^{Glu}, has been shown to repress reporter gene expression and promote RSV replication. As another example of a tRF with a positive effect, a 3'-CCA tRF from tRNA^{Pro} has been suggested to function as a primer for reverse transcription of human T-cell leukemia virus-1 (HTLV-1) [67].

Maute *et al.* also reported an example of a tRF that functions as a miRNA in mature human B cells [53]. In these cells, a 22 nt 3'-CCA tRF derived from tRNA^{Gly} is generated in a Dicer-dependent manner and associated with AGO proteins. The 3'-CCA tRF was shown to repress the expression of target mRNAs in a sequence-specific manner. RPA1, an essential gene for DNA dynamics and repair, was identified as the endogenous target containing complementary sequences in its 3'-UTR. Indeed, expression of this tRF suppresses cell proliferation and modulates the response to DNA damage, indicating the clear biological importance of this tRF [53]. While the endogenous targets and biological functions of most of AGO-binding tRFs remain obscure, Haussecker *et al.* used reporter assay to confirm that AGO-bound 3'-CCA tRFs and 3'-U tRFs silenced complementary target RNAs [51]. One of the tRFs used in their analysis, a 3'-U tRF derived from tRNA^{SerUGA}, was also reported to promote cell proliferation by Lee *et al.* [58], which validates its cellular role, although it is unknown whether or not interaction with AGO is required for the function of this tRF. Accumulation of further evidence of the functionality and endogenous biological roles of AGO-bound tRFs could result in clear-cut designation of these tRFs as small regulatory RNA molecules.

In addition to the AGO-bound tRFs, tRNA fragments are implicated in the AGO-independent sequence-specific silencing of target RNAs by binding to tRNA processing enzymes. Nashimoto *et al.* showed that RNase Z, when associated with a small guide RNA (sgRNA), can cleave target mRNAs bearing a binding site complementary to the sequence of sgRNAs [68, 69]. Intriguingly, this silencing, referred to as TRUE (tRNase Z^L-utilizing efficacious) silencing, can utilize 5'-tRNA halves as sgRNAs *in vitro* and *in vivo* for efficient silencing of complementary target RNAs [70]. PPM1F mRNA was identified as one of the endogenous targets of a 5'-tRNA half derived from tRNA^{Gln}. These findings imply a physiological role for the complex of RNase Z and 5'-tRNA halves in apoptosis, because both RNase Z and PPM1F are implicated in the regulation of apoptosis.

Future perspectives

An increasing number of reports have revealed the abundant expression of functional tRNA fragments; thus, it now appears highly plausible that cells use tRNAs as a source for small functional RNAs to modulate biological processes beyond translation. However, research on tRNA fragments is still in the beginning stage; information regarding tRNA fragment expression profiles is still fragmented, and the molecular basis behind the biogenesis and function of tRNA fragments remain elusive.

The immediate focus should be to capture the comprehensive repertoire of tRNA fragments in different tissues and cells by creating libraries and accurately profiling them or by re-evaluating available NGS data sets. However, the biological properties of tRNA fragments could make these attempts challenging. One such property is the presence of post-transcriptional modifications within tRNA fragments. Because tRNA fragments contain non-canonical modified nucleotides of mature tRNAs, many of which inhibit Watson-Crick base pairing and thus cause arrest of reverse-transcription or abnormal read through by reverse transcriptase [71], using tRNA fragments to prepare cDNA could result in mutations or severe reductions in the quantity of the resulting cDNAs. Therefore, tRNA fragments

from heavily modified mature tRNAs could be underrepresented in sequencing data. This problem is inevitable with any sequencing technology used for detection and quantification of RNA, because there is no experimental methodology to remove all tRNA modifications. Another property that must be considered is the terminal modification of tRNA fragments. The tRNA fragments derived from the 3'-part of mature tRNAs, such as 3'-tRNA halves and 3'-CCA tRFs, contain an amino acid at their 3'-end. Furthermore, the 5'-part of ANG-generating fragments such as 5'-tRNA halves could contain a cyclic-phosphate at their 3'-end [72]. The preparation of cDNA without adequate procedures to remove these terminal modifications will result in severe underrepresentation of these tRNA fragments. If tRNA fragments are produced from the 5'-leader sequences of pre-tRNAs, their 5'-end would contain a triphosphate modification [43]. Normal RNA sequencing methods do not include a procedure to remove 5'-triphosphates, which may be one of the reasons why tRFs from 5'-leader sequences have not yet been widely discovered. It is crucial to produce libraries and interpret sequencing data from these biochemical perspectives, and to confirm the observations using less-biased alternative techniques, such as northern blot or tRNA microarray [28, 73].

To discriminate functional tRNA fragments from “meaningless” degradation products, it is imperative to biochemically elucidate the factors in their biogenesis and to determine their molecular functions. This could be achieved by analyzing their localization, identifying the proteins with which they interact, and examining various biological phenomena in their presence and absence. Regarding localization, for example, 3'-U tRFs accumulate in the cytosol, although their biogenesis occurs in the nucleus [74], suggesting that 3'-U tRFs are actively exported and exert their function in the cytoplasm. As AGO-binding property of RNAs speculates miRNA-like role for the RNAs, identification of interacting proteins is particularly important to address the biological role of tRNA fragments. Bioinformatics studies with support from biochemical assays have identified numerous novel tRNA-interacting proteins [75], implying that the biological functions of tRNAs and their fragments may be way beyond our expectations. Further combination of computational and biochemical efforts will significantly advance our understanding of functional tRNA fragments and expand our knowledge regarding the tRNA world.

Acknowledgments

We are grateful to the members of the authors' lab for helpful discussions. Work in the lab on this topic was supported in part by a grant (GM106047 to YK) from the National Institutes of Health.

References

1. Esteller M. Non-coding RNAs in human disease. *Nat Rev Genet.* 2011; 12(12):861–74. [PubMed: 22094949]
2. Farazi TA, Juranek SA, Tuschl T. The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. *Development.* 2008; 135(7):1201–14. [PubMed: 18287206]
3. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. *Nat Rev Genet.* 2009; 10(2):94–108. [PubMed: 19148191]
4. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. *Nat Rev Mol Cell Biol.* 2009; 10(2):126–39. [PubMed: 19165215]

5. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res.* 2014; 42(Database issue):D68–73. [PubMed: 24275495]
6. Friedman RC, et al. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* 2009; 19(1):92–105. [PubMed: 18955434]
7. RajBhandary, UL.; Soll, D. Transfer RNA in Its Fourth Decade. In: Soll, D.; RajBhandary, UL., editors. *tRNA: Structure, Biosynthesis and Function*. American Society for Microbiology; Washington, D.C: 1995. p. 1-4.
8. Lowe TM, Eddy SR. tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. *Nucleic Acids Res.* 1997; 25(5):955–64. [PubMed: 9023104]
9. Nwagwu M, Nana M. Ribonucleic acid synthesis in embryonic chick muscle, rates of synthesis and half-lives of transfer and ribosomal RNA species. *J Embryol Exp Morphol.* 1980; 56:253–67. [PubMed: 7400745]
10. Kanerva PA, Maenpaa PH. Codon-specific serine transfer ribonucleic acid degradation in avian liver during vitellogenin induction. *Acta Chem Scand B.* 1981; 35 (5):379–85. [PubMed: 6914867]
11. Raina M, Ibba M. tRNAs as regulators of biological processes. *Front Genet.* 2014; 5:171. [PubMed: 24966867]
12. Gebetsberger J, Polacek N. Slicing tRNAs to boost functional ncRNA diversity. *RNA Biol.* 2013; 10(12):1798–806. [PubMed: 24351723]
13. Garcia-Silva MR, et al. Hints of tRNA-Derived Small RNAs Role in RNA Silencing Mechanisms. *Genes (Basel).* 2012; 3(4):603–14. [PubMed: 24705078]
14. Sobala A, Hutvagner G. Transfer RNA-derived fragments: origins, processing, and functions. *Wiley Interdiscip Rev RNA.* 2011; 2(6):853–62. [PubMed: 21976287]
15. Phizicky EM, Hopper AK. tRNA biology charges to the front. *Genes Dev.* 2010; 24 (17):1832–60. [PubMed: 20810645]
16. Zhao H, et al. New role for tRNA and its fragment purified from human urinary bladder carcinoma conditioned medium: inhibition of endothelial cell growth. *J Cell Biochem.* 1999; 76(1):109–17. [PubMed: 10581005]
17. Nowacka M, et al. Identification of stable, high copy number, medium-sized RNA degradation intermediates that accumulate in plants under non-stress conditions. *Plant Mol Biol.* 2013; 83(3): 191–204. [PubMed: 23708952]
18. Nie Z, et al. RIP-seq of BmAgo2-associated small RNAs reveal various types of small non-coding RNAs in the silkworm, *Bombyx mori*. *BMC Genomics.* 2013; 14:661. [PubMed: 24074203]
19. Blanco S, et al. Aberrant methylation of tRNAs links cellular stress to neuro-developmental disorders. *EMBO J.* 2014
20. Durdevic Z, et al. The RNA methyltransferase Dnmt2 is required for efficient Dicer-2-dependent siRNA pathway activity in *Drosophila*. *Cell Rep.* 2013; 4(5):931–7. [PubMed: 24012760]
21. Hsieh LC, et al. Uncovering small RNA-mediated responses to phosphate deficiency in *Arabidopsis* by deep sequencing. *Plant Physiol.* 2009; 151(4):2120–32. [PubMed: 19854858]
22. Lee SR, Collins K. Starvation-induced cleavage of the tRNA anticodon loop in *Tetrahymena thermophila*. *J Biol Chem.* 2005; 280(52):42744–9. [PubMed: 16272149]
23. Thompson DM, et al. tRNA cleavage is a conserved response to oxidative stress in eukaryotes. *RNA.* 2008; 14(10):2095–103. [PubMed: 18719243]
24. Thompson DM, Parker R. The RNase Rny1p cleaves tRNAs and promotes cell death during oxidative stress in *Saccharomyces cerevisiae*. *J Cell Biol.* 2009; 185(1):43–50. [PubMed: 19332891]
25. Yamasaki S, et al. Angiogenin cleaves tRNA and promotes stress-induced translational repression. *J Cell Biol.* 2009; 185(1):35–42. [PubMed: 19332886]
26. Fu H, et al. Stress induces tRNA cleavage by angiogenin in mammalian cells. *FEBS Lett.* 2009; 583(2):437–42. [PubMed: 19114040]
27. Thompson DM, Parker R. Stressing out over tRNA cleavage. *Cell.* 2009; 138(2):215–9. [PubMed: 19632169]

28. Saikia M, et al. Genome-wide identification and quantitative analysis of cleaved tRNA fragments induced by cellular stress. *J Biol Chem.* 2012; 287(51):42708–25. [PubMed: 23086926]
29. Li Y, et al. Stress-induced tRNA-derived RNAs: a novel class of small RNAs in the primitive eukaryote *Giardia lamblia*. *Nucleic Acids Res.* 2008; 36(19):6048–55. [PubMed: 18820301]
30. Garcia-Silva MR, et al. A population of tRNA-derived small RNAs is actively produced in *Trypanosoma cruzi* and recruited to specific cytoplasmic granules. *Mol Biochem Parasitol.* 2010; 171(2):64–73. [PubMed: 20156490]
31. Dhahbi JM, et al. 5' tRNA halves are present as abundant complexes in serum, concentrated in blood cells, and modulated by aging and calorie restriction. *BMC Genomics.* 2013; 14:298. [PubMed: 23638709]
32. Peng H, et al. A novel class of tRNA-derived small RNAs extremely enriched in mature mouse sperm. *Cell Res.* 2012; 22(11):1609–12. [PubMed: 23044802]
33. Galizi R, et al. Evidence of tRNA cleavage in apicomplexan parasites: Half-tRNAs as new potential regulatory molecules of *Toxoplasma gondii* and *Plasmodium berghei*. *Mol Biochem Parasitol.* 2013; 188(2):99–108. [PubMed: 23557708]
34. Goll MG, et al. Methylation of tRNA^{Asp} by the DNA methyltransferase homolog Dnmt2. *Science.* 2006; 311(5759):395–8. [PubMed: 16424344]
35. Schaefer M, et al. RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage. *Genes Dev.* 2010; 24(15):1590–5. [PubMed: 20679393]
36. Emará MM, et al. Angiogenin-induced tRNA-derived stress-induced RNAs promote stress-induced stress granule assembly. *J Biol Chem.* 2010; 285(14):10959–68. [PubMed: 20129916]
37. Adjibade P, Mazroui R. Control of mRNA turnover: Implication of cytoplasmic RNA granules. *Semin Cell Dev Biol.* 2014
38. Saikia M, et al. Angiogenin-cleaved tRNA halves interact with cytochrome c, protecting cells from apoptosis during osmotic stress. *Mol Cell Biol.* 2014; 34(13):2450–63. [PubMed: 24752898]
39. Schaffer AE, et al. CLP1 founder mutation links tRNA splicing and maturation to cerebellar development and neurodegeneration. *Cell.* 2014; 157(3):651–63. [PubMed: 24766810]
40. Karaca E, et al. Human CLP1 mutations alter tRNA biogenesis, affecting both peripheral and central nervous system function. *Cell.* 2014; 157(3):636–50. [PubMed: 24766809]
41. Weitzer S, et al. CLP1 as a novel player in linking tRNA splicing to neurodegenerative disorders. *Wiley Interdiscip Rev RNA.* 2014
42. Weitzer S, Martínez J. The human RNA kinase hClp1 is active on 3' transfer RNA exons and short interfering RNAs. *Nature.* 2007; 447(7141):222–6. [PubMed: 17495927]
43. Hanada T, et al. CLP1 links tRNA metabolism to progressive motor-neuron loss. *Nature.* 2013; 495(7442):474–80. [PubMed: 23474986]
44. Ivanov P, et al. Angiogenin-induced tRNA fragments inhibit translation initiation. *Mol Cell.* 2011; 43(4):613–23. [PubMed: 21855800]
45. Zhang S, Sun L, Kragler F. The phloem-delivered RNA pool contains small noncoding RNAs and interferes with translation. *Plant Physiol.* 2009; 150(1):378–87. [PubMed: 19261735]
46. Sobala A, Hutvagner G. Small RNAs derived from the 5' end of tRNA can inhibit protein translation in human cells. *RNA Biol.* 2013; 10(4):553–63. [PubMed: 23563448]
47. Gebetsberger J, et al. tRNA-derived fragments target the ribosome and function as regulatory non-coding RNA in *Haloferax volcanii*. *Archaea.* 2012; 2012:260909. [PubMed: 23326205]
48. Suzuki R, Honda S, Kirino Y. PIWI Expression and Function in Cancer. *Front Genet.* 2012; 3:204. [PubMed: 23087701]
49. Kawamura Y, et al. Drosophila endogenous small RNAs bind to Argonaute 2 in somatic cells. *Nature.* 2008; 453(7196):793–7. [PubMed: 18463636]
50. Loss-Morais G, Waterhouse PM, Margis R. Description of plant tRNA-derived RNA fragments (tRFs) associated with argonaute and identification of their putative targets. *Biol Direct.* 2013; 8:6. [PubMed: 23402430]
51. Haussecker D, et al. Human tRNA-derived small RNAs in the global regulation of RNA silencing. *RNA.* 2010; 16(4):673–95. [PubMed: 20181738]

52. Burroughs AM, et al. Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin. *RNA Biol.* 2011; 8(1):158–77. [PubMed: 21282978]
53. Maute RL, et al. tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma. *Proc Natl Acad Sci U S A.* 2013; 110(4):1404–9. [PubMed: 23297232]
54. Li Z, et al. Extensive terminal and asymmetric processing of small RNAs from rRNAs, snoRNAs, snRNAs, and tRNAs. *Nucleic Acids Res.* 2012; 40(14):6787–99. [PubMed: 22492706]
55. Cole C, et al. Filtering of deep sequencing data reveals the existence of abundant Dicer-dependent small RNAs derived from tRNAs. *RNA.* 2009; 15(12):2147–60. [PubMed: 19850906]
56. Morin RD, et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. *Genome Res.* 2008; 18(4):610–21. [PubMed: 18285502]
57. Babiarz JE, et al. Mouse ES cells express endogenous shRNAs, siRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. *Genes Dev.* 2008; 22(20):2773–85. [PubMed: 18923076]
58. Lee YS, et al. A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). *Genes Dev.* 2009; 23(22):2639–49. [PubMed: 19933153]
59. Keam SP, et al. The human Piwi protein Hiwi2 associates with tRNA-derived piRNAs in somatic cells. *Nucleic Acids Res.* 2014
60. Hirano T, et al. Small RNA profiling and characterization of piRNA clusters in the adult testes of the common marmoset, a model primate. *RNA.* 2014; 20(8):1223–37. [PubMed: 24914035]
61. Brennecke J, et al. Discrete small RNA-generating loci as master regulators of transposon activity in *Drosophila*. *Cell.* 2007; 128(6):1089–103. [PubMed: 17346786]
62. Garcia-Silva MR, et al. A particular set of small non-coding RNAs is bound to the distinctive Argonaute protein of *Trypanosoma cruzi*: insights from RNA-interference deficient organisms. *Gene.* 2014; 538(2):379–84. [PubMed: 24463018]
63. Couvillion MT, Sachidanandam R, Collins K. A growth-essential *Tetrahymena* Piwi protein carries tRNA fragment cargo. *Genes Dev.* 2010; 24(24):2742–7. [PubMed: 21106669]
64. Couvillion MT, et al. A *Tetrahymena* Piwi bound to mature tRNA 3' fragments activates the exonuclease Xrn2 for RNA processing in the nucleus. *Mol Cell.* 2012; 48 (4):509–20. [PubMed: 23084833]
65. Yeung ML, et al. Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid. *Nucleic Acids Res.* 2009; 37(19):6575–86. [PubMed: 19729508]
66. Wang Q, et al. Identification and functional characterization of tRNA-derived RNA fragments (tRFs) in respiratory syncytial virus infection. *Mol Ther.* 2013; 21(2):368–79. [PubMed: 23183536]
67. Ruggero K, et al. Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. *J Virol.* 2014; 88(7):3612–22. [PubMed: 24403582]
68. Nashimoto M. Specific cleavage of target RNAs from HIV-1 with 5' half tRNA by mammalian tRNA 3' processing endoribonuclease. *RNA.* 1996; 2(6):523–4. [PubMed: 8718682]
69. Nakashima A, et al. Gene silencing by the tRNA maturase tRNase ZL under the direction of small-guide RNA. *Gene Ther.* 2007; 14(1):78–85. [PubMed: 16885998]
70. Elbarbary RA, et al. Modulation of gene expression by human cytosolic tRNase Z(L) through 5'-half-tRNA. *PLoS One.* 2009; 4(6):e5908. [PubMed: 19526060]
71. Kellner S, Burhenne J, Helm M. Detection of RNA modifications. *RNA Biol.* 2010; 7(2):237–47. [PubMed: 20224293]
72. Rybak SM, Vallee BL. Base cleavage specificity of angiogenin with *Saccharomyces cerevisiae* and *Escherichia coli* 5S RNAs. *Biochemistry.* 1988; 27(7):2288–94. [PubMed: 3289612]
73. Dittmar KA, Goodenbour JM, Pan T. Tissue-specific differences in human transfer RNA expression. *PLoS Genet.* 2006; 2(12):e221. [PubMed: 17194224]

74. Liao JY, et al. Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of miRNAs and tRNA 3' trailers. *PLoS One*. 2010; 5(5):e10563. [PubMed: 20498841]
75. Parisien M, et al. Discovering RNA-protein interactome by using chemical context profiling of the RNA-protein interface. *Cell Rep*. 2013; 3(5):1703–13. [PubMed: 23665222]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1.
 (A) tRNA fragments derived from precursor or mature tRNAs and their processing enzymes.
 (B) Reported molecular functions of tRNA fragments.

Table 1

Summary of the tRNA fragment studies that investigated molecular functions and/or associated proteins of tRNA fragments.

| Organism | Material | Detected tRNA fragment | Responsible nuclease | Associated protein | Function | tRNA fragment used for functional analysis | Reference |
|----------|---------------------------------|----------------------------------|----------------------|--------------------|---|--|-----------|
| Human | Urinary bladder carcinoma cells | | | | Inhibit endothelial cell growth | Mixture | [16] |
| | Fibroblast | 5'-half | ANG | | Induce stress and lead to cell death | AspGUC | [19] |
| | U2OS | 5'-half | ANG | | Inhibit translation | Mixture | [25] |
| | U2OS | 5'-half | ANG | | Promote SG assembly | AlaAGC, GlyCCC, ValAAC/CAC | [36] |
| | Fibroblast | | ANG | | Increase stress sensitivity and lead to cell death | TyrGUA (3'-half without 5'-P) | [39] |
| | U2OS | 5'-half | ANG | YB-1 | Inhibit translation initiation by displacing eIF4G/A and eIF4F | Mixture, AlaAGC, CysGCA | [44] |
| | HeLa | 5'-tRF | | | Inhibit translation | GlnCUG | [46] |
| | HEK293 | 3'-CCA tRF, 3'-U tRF | Dicer, RNase Z | AGO | Inhibit translation | SerUGA | [51] |
| | THP-1 | 5'-half, 3'-half, 5'-tRF, 3'-tRF | | AGO1, 2, 3 | | | [52] |
| | B cell lymphoma | 3'-CCA tRF | Dicer | AGO | Inhibit translation, suppress cell proliferation by RPA1 repression | GlyGCC | [53] |
| | HEK293 | 5'-tRF | Dicer | AGO1, 2 | | HisGUG, LeuCAG | [55] |
| | HCT116 | 3'-U tRF | RNase Z | | Promote cell proliferation | SerUGA | [58] |
| | MDA-MB-231 | 5'-half, 3'-half, 5'-tRF | | HIW12 | | | [59] |
| | A549 | 5'-half, 5'-tRF | ANG | | Inhibit translation, promote RSV replication | GluCUC | [66] |
| | HEK293 | 5'-half | | RNase Z | Cleave target RNA, modulate apoptosis by PPM1F repression | GluGUC | [70] |
| Mouse | MEF | 5'-half | | | Inhibit translation | Mixture | [25] |
| | MEF | 5'-half | | Cyt c | Inhibit apoptosis | ArgACG | [38] |
| | NSC-34 | 5'-leader-exon tRF | TSEN | | Promote p53 phosphorylation upon oxidative stress | TyrGUA | [43] |
| Marmoset | Testis | 5'-tRF | | MARWI | | | [60] |

| Organism | Material | Detected tRNA fragment | Responsible nuclease | Associated protein | Function | tRNA fragment used for functional analysis | Reference |
|--------------------------------|------------|--|----------------------|--------------------|---|--|-----------|
| <i>Bombyx mori</i> | BmN | 5'-half, 5'-IRF, 3'-half, 3'-CCA IRF, 3'-U IRF | | AGO2 | | | [18] |
| <i>Trypanosoma cruzi</i> | | 5'-half | | TePWI | | | [62] |
| <i>Tetrahymena thermophila</i> | | 5'-IRF 3'-CCA IRF | | TW112 | | | [63] |
| <i>Haloferax volcanii</i> | | 3'-CCA IRF | | TW112 | Localize TW112 in nuclear and activate Xrn2 | | [64] |
| <i>Cucurbita maxima</i> | Phloem sap | 5'-IRF, 3'-IRF | | Ribosome | Inhibit peptide bond formation in translation | ValGAC | [47] |
| <i>Arabidopsis thaliana</i> | | 5'-half, 3'-half | | | | | [45] |
| | | 5'-IRF, 3'-CCA IRF | | AGO1, 2, 4, 7 | | | [50] |

Shigenatsu et al.